U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Medical Devices
  3. Products and Medical Procedures
  4. Device Approvals and Clearances
  5. Recently-Approved Devices
  6. LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus – P220034
  1. Recently-Approved Devices

LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus – P220034

LIAISON Biotrin Parvovirus B19 IgG Plus is a lab test used to detect parvovirus B19 antibody. Control Parvovirus B19 IgG Plus is used as a quality control test.

 


This is a brief overview of information related to the FDA’s approval to market this product. See the links below to the Summary of Safety and Effectiveness Data (SSED) and product labeling for more complete information on this product, its indications for use, and the basis for the FDA’s approval. 

Product Name: LIAISON Biotrin Parvovirus B19 IgG Plus LIAISON Biotrin Control Parvovirus B19 IgG Plus
PMA Applicant: DiaSorin Inc.
Address: 1951 Northwestern Avenue, Stillwater, MN 55082
Approval Date: March 29, 2024
Approval Letter: Approval Order

What is it?

The LIAISON Biotrin Parvovirus B19 IgG Plus is a laboratory test used to detect human parvovirus IgG antibodies against the parvovirus B19 antigen in the blood. This test is used with the LIAISON XL analyzer that runs the lab test and analyzes the results. The LIAISON Biotrin Control Parvovirus B19 IgG Plus is used as a quality control to ensure that the test is working properly.

Back to Top